Back

Boreas

Official Title

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation

Study Details

The purpose of the study is to investigate the effect of the study drug on lung function, exacerbation's and quality of life in patients with COPD.

Principal Investigator

Dr. Kaharu Sumino

IRB Number

201905057

Eligibility

1. Participants must be 40 to 80 years of age and must have a history of smoking
2. Participants must have a physician diagnosis of COPD
3. Participants must not have pulmonary disease other than COPD

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back